Your browser doesn't support javascript.
loading
Prediction of Response to Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma Based on MRI Radiomics and Delta Radiomics: A Two-Center Retrospective Study.
Xi, Yuzhen; Ge, Xiuhong; Ji, Haiming; Wang, Luoyu; Duan, Shaofeng; Chen, Haonan; Wang, Mengze; Hu, Hongjie; Jiang, Feng; Ding, Zhongxiang.
Afiliación
  • Xi Y; Department of Radiology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
  • Ge X; Department of Radiology, 903rd Hospital of PLA, Hangzhou, China.
  • Ji H; Department of Radiology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
  • Wang L; Department of Radiology, Liangzhu Hospital, Hangzhou, China.
  • Duan S; Department of Radiology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
  • Chen H; GE Healthcare, Precision Health Institution, Shanghai, China.
  • Wang M; Zhejiang Chinese Medical University, Hangzhou, China.
  • Hu H; Zhejiang Chinese Medical University, Hangzhou, China.
  • Jiang F; Department of Radiology, Sir Run Run Shaw Hospital Affiliated to Medical College Zhejiang University, Hangzhou, China.
  • Ding Z; Department of Head and Neck Radiotherapy, Zhejiang Cancer Hospital/Zhejiang Province Key Laboratory of Radiation Oncology, Hangzhou, China.
Front Oncol ; 12: 824509, 2022.
Article en En | MEDLINE | ID: mdl-35530350
Objective: We aimed to establish an MRI radiomics model and a Delta radiomics model to predict tumor retraction after induction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT) for primary nasopharyngeal carcinoma (NPC) in non-endemic areas and to validate its efficacy. Methods: A total of 272 patients (155 in the training set, 66 in the internal validation set, and 51 in the external validation set) with biopsy pathologically confirmed primary NPC who were screened for pretreatment MRI were retrospectively collected. The NPC tumor was delineated as a region of interest in the two sequenced images of MRI before treatment and after IC, followed by radiomics feature extraction. With the use of maximum relevance minimum redundancy (mRMR) and least absolute shrinkage and selection operator (LASSO) algorithms, logistic regression was performed to establish pretreatment MRI radiomics and pre- and post-IC Delta radiomics models. The optimal Youden's index was taken; the receiver operating characteristic (ROC) curve, calibration curve, and decision curve were drawn to evaluate the predictive efficacy of different models. Results: Seven optimal feature subsets were selected from the pretreatment MRI radiomics model, and twelve optimal subsets were selected from the Delta radiomics model. The area under the ROC curve, accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of the MRI radiomics model were 0.865, 0.827, 0.837, 0.813, 0.776, and 0.865, respectively; the corresponding indicators of the Delta radiomics model were 0.941, 0.883, 0.793, 0.968, 0.833, and 0.958, respectively. Conclusion: The pretreatment MRI radiomics model and pre- and post-IC Delta radiomics models could predict the IC-CCRT response of NPC in non-epidemic areas.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China